Samuel Kintz - 17 Jun 2025 Form 4 Insider Report for Enliven Therapeutics, Inc. (ELVN)

Role
PRESIDENT AND CEO, Director
Signature
/s/ Ben Hohl, by power of attorney
Issuer symbol
ELVN
Transactions as of
17 Jun 2025
Net transactions value
-$277,292
Form type
4
Filing time
18 Jun 2025, 18:22:48 UTC
Previous filing
05 Jun 2025
Next filing
21 Jul 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Kintz Samuel PRESIDENT AND CEO, Director C/O ENLIVEN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, BOULDER /s/ Ben Hohl, by power of attorney 18 Jun 2025 0001967168

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELVN Common Stock Sale $231,839 -10,502 -1.1% $22.08 954,890 17 Jun 2025 See footnote F1, F2, F3
transaction ELVN Common Stock Sale $45,453 -1,998 -0.21% $22.75 952,892 17 Jun 2025 See footnote F1, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.
F2 This transaction was executed in multiple trades at prices ranging from $21.5935 to $22.5793. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3 The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee.
F4 This transaction was executed in multiple trades at prices ranging from $22.5945 to $22.9964. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.